Post hoc analysis of SELECT (17,604 adults with cardiovascular disease and overweight, without diabetes): semaglutide's cardiovascular benefit did not differ detectably by frailty. Quality-of-life gains looked larger in frailer patients.
Secondary analysisn = 17,604
Ostrominski et al. Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial